ASCT in primary refractory multiple myeloma
| Reference . | No. of patients . | Age, y . | β2M, mg/L . | CR, % . | Median EFS, y . | Median OS, y . |
|---|---|---|---|---|---|---|
| Alexanian et al,17 (1994) | 27 | 45 | 2.8 | 8 | 3.5 | 6 |
| Vesole et al18 (1994) | 72 | 50 | — | 15 | 1.7 | 4 |
| Singhal et al19 (2002) | 43 | 54 | 3.3 | 40 | 2 | — |
| Kumar et al20 (2004) | 50 | 56 | 2.7 | 20 | 2.5 | 5 |
| Alexanian et al21 (2004) | 89 | 52 | 3.7 | 16 | 7* | 7* |
| Reference . | No. of patients . | Age, y . | β2M, mg/L . | CR, % . | Median EFS, y . | Median OS, y . |
|---|---|---|---|---|---|---|
| Alexanian et al,17 (1994) | 27 | 45 | 2.8 | 8 | 3.5 | 6 |
| Vesole et al18 (1994) | 72 | 50 | — | 15 | 1.7 | 4 |
| Singhal et al19 (2002) | 43 | 54 | 3.3 | 40 | 2 | — |
| Kumar et al20 (2004) | 50 | 56 | 2.7 | 20 | 2.5 | 5 |
| Alexanian et al21 (2004) | 89 | 52 | 3.7 | 16 | 7* | 7* |
ASCT indicates autologous stem cell transplantation; β2M, β2-microglobulin; CR, complete remission; EFS, event-free survival; OS, overall survival; and —, not applicable.
In patients achieving CR after ASCT.